Lutathera

Chemical Namelutetium Lu 177 dotatate
Dosage FormInjectable (intravenous; 370 MBq/mL (10 mCi/mL))
Drug ClassHormones
SystemEndocrine
CompanyAAA USA Inc.
Approval Year2018

Indication

  • Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Last updated on 10/27/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?